基因治疗公司Adverum(ADVM.US)盘前跳涨!获礼来(LLY.US)收购要约

智通财经
Oct 24

智通财经APP获悉,制药巨头礼来(LLY.US)周五公布了收购基因治疗公司Adverum Biotechnologies(ADVM.US)及其主要基因治疗候选药物Ixo-vec的计划。受此消息提振,Adverum周五美股盘前一度涨近29%,截至发稿涨幅缩窄至逾6%。

根据协议,礼来将发起收购要约,以每股3.56美元的价格收购所有已发行的Adverum股票。该协议还附带一项或有价值权(CVR),若满足特定里程碑条件,每股可额外获得最高8.91美元,使交易总潜在价值达到每股12.47美元。

据悉,Adverum专注于开发玻璃体腔内单次给药基因疗法,旨在研发可恢复视力、防止失明的功能性治愈方案。其核心产品候选药物Ixo-vec是一种用于治疗湿性老年黄斑变性(wAMD)的玻璃体腔内基因疗法。

礼来表示,此次收购将结合其基因药物研发能力与Adverum在眼科基因疗法领域的技术优势,有助于拓展基因疗法在减轻年龄相关疾病负担方面的潜力。该交易预计将在2025年第四季度完成,需满足惯常的交割条件。

此外,若要约收购成功完成,礼来将通过第二步合并(second-step merger)收购所有未在要约中被涉及的Adverum股份,收购价格与要约条件一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10